We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-19.07%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$129M
AUM Growth
-$22M
Cap. Flow
-$11.1M
Cap. Flow %
-8.62%
Top 10 Hldgs %
47.53%
Holding
65
New
8
Increased
16
Reduced
26
Closed
13

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$3.31M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$2.19M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.82M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$994K
5
SDS icon
ProShares UltraShort S&P500
SDS
+$967K

Top Sells

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$10.7M
2
GILD icon
Gilead Sciences
GILD
+$2.74M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$1.5M
4
XNCR icon
Xencor
XNCR
+$1.32M
5
AMGN icon
Amgen
AMGN
+$1.28M

Sector Composition

Rank Sector Weight
1 Healthcare 73.12%
2 Miscellaneous 26.17%
3 Real Estate 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCRX icon
26
Pacira BioSciences
PCRX
$1.03B
$1.86M 1.44%
35,110
+16,000
+84% +$936K
VCEL icon
27
Vericel Corp
VCEL
$2.11B
$1.75M 1.35%
298,941
-33,216
-10% -$93.1K
CLVS
28
DELISTED
Clovis Oncology, Inc.
CLVS
$1.44M 1.11%
75,000
+25,000
+50% +$529K
HOLX
29
DELISTED
Hologic
HOLX
$1.33M 1.03%
38,700
-9,300
-19% -$324K
MDCO
30
DELISTED
Medicines Co
MDCO
$1.29M 1%
40,500
+15,500
+62% +$506K
LOXO
31
DELISTED
Loxo Oncology, Inc
LOXO
$984K 0.76%
36,000
-24,000
-40% -$502K
ONCE
32
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$930K 0.72%
+31,500
New +$994K
SNR
33
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$927K 0.72%
+90,000
New +$843K
RARE icon
34
Ultragenyx Pharmaceutical
RARE
$2.59B
$855K 0.66%
+13,500
New +$883K
SDS icon
35
ProShares UltraShort S&P500
SDS
$391M
$853K 0.66%
+450
New +$967K
ADMS
36
DELISTED
Adamas Pharmaceuticals
ADMS
$781K 0.6%
54,000
-26,000
-33% -$438K
ACHN
37
DELISTED
Achillion Pharmaceuticals
ACHN
$764K 0.59%
99,000
-1,000
-1% -$7.32K
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
$763K 0.59%
69,109
+12,321
+22% +$122K
MACK
39
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$753K 0.58%
11,439
-4,131
-27% -$216K
PRTK
40
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$683K 0.53%
45,000
-15,000
-25% -$229K
MCRB icon
41
Seres Therapeutics
MCRB
$49.7M
$645K 0.5%
1,215
-435
-26% -$227K
ZGNX
42
DELISTED
Zogenix, Inc.
ZGNX
$630K 0.49%
68,130
-27,570
-29% -$276K
DRNA
43
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$579K 0.45%
108,000
+8,000
+8% +$50.5K
RXDX
44
DELISTED
Ignyta, Inc.
RXDX
$548K 0.42%
81,000
-19,000
-19% -$156K
ISEE
45
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$533K 0.41%
12,600
-4,400
-26% -$224K
EYPT icon
46
EyePoint Inc
EYPT
$399M
$482K 0.37%
+18,000
New +$569K
KPTI icon
47
Karyopharm Therapeutics
KPTI
$44M
$442K 0.34%
3,300
-700
-18% -$77.3K
UTHR icon
48
United Therapeutics
UTHR
$22.6B
$429K 0.33%
3,848
-2,666
-41% -$337K
LAB icon
49
Standard BioTools
LAB
$256M
$363K 0.28%
45,000
-25,000
-36% -$180K
LABU icon
50
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$720M
$329K 0.25%
+599
New +$379K
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q1 2016 Portfolio in Review

As of Q1 2016, Opus Point Partners Management held 65 positions worth $129M, down 15% from $151M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Opus Point Partners Management withdrew a net $11.1M in Q1 2016, closing 13 positions and reducing 26 holdings. Its most notable exit was iShares Biotechnology ETF, an estimated $10.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in Pfizer worth $3.26M.

  • Opus Point Partners Management's largest Q1 2016 buy was Pfizer: 115,940 shares worth $3.26M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q1 2016, an estimated $2.19M increase.
  • Opus Point Partners Management's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $2.74M.
  • Opus Point Partners Management fully exited iShares Biotechnology ETF in Q1 2016, selling an estimated $10.7M.
  • Opus Point Partners Management's ten largest holdings make up 48% of its $129M portfolio in Q1 2016.
  • Opus Point Partners Management opened 8 new positions and closed 13 in Q1 2016.
  • Opus Point Partners Management's portfolio value fell 15% quarter-over-quarter to $129M.

Based on Opus Point Partners Management's 13F filing for Q1 2016, filed 13 May 2016.